Prescribing information for LUTATHERA® (lutetium (177Lu) oxodotreotide) (external link)
Prescribing information for Pluvicto®▼ (lutetium (177Lu) vipivotide tetraxetan) (external link)
Prescribing information for Locametz®▼ (gozetotide) (external link)
Prescribing information for SomaKit TOC® (edotreotide) (external link)
This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.
Radioligand therapy (RLT)
The science of RLT and Novartis RLT services
The science of RLT and Novartis RLT services
Explore RLT Services
Explore RLT Services
RLT manufacturing and logistics
RLT manufacturing and logistics
Find an RLT treatment centre
Find an RLT treatment centre
LUTATHERA® (lutetium [177Lu] oxodotreotide)
PLUVICTO®▼ (lutetium [177Lu] vipivotide tetraxetan)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
